Paul Nghiem
www.merkelcell.org
0000-0003-2784-963X
University of Washington
297 papers found
Refreshing results…
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
Single Fraction Radiotherapy as Postoperative Treatment (SF-PORT) for Resected, Stage I/II Merkel Cell Carcinoma
Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice
Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Response to “Mohs surgery for early‐stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision +/− radiation therapy with no increase in MCC‐specific death”
Spatial transcriptomics at subspot resolution with BayesSpace
Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.
In Regard to Barker
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients
How we treat Merkel cell carcinoma: within and beyond current guidelines
Missing publications? Search for publications with a matching author name.